Statin therapy reduces contrast-induced nephropathy: An analysis of contemporary percutaneous interventions - 21/08/11
, Nizar Attallah, MD b, Dean E. Smith, PhD c, Eva Kline-Rogers, RN c, David Share, MD d, Michael J. O’Donnell, MD e, Mauro Moscucci, MD c
Requests for reprints should be addressed to Sanjaya Khanal, MD, Interventional Cardiovascular Fellowship, Heart and Vascular Institute, K-2, Henry Ford Hospital, 2799 W Grand Blvd., Detroit, MI 48202.Abstract |
Purpose |
We sought to examine whether statin therapy before percutaneous coronary intervention results in reduction in contrast-induced nephropathy (CIN). Intravascular administration of contrast media can have nephrotoxic effects, particularly in patients with baseline renal insufficiency. Along with lowering serum cholesterol, statins have pleiotropic effects in the vasculature. The effect of statin use on CIN is unknown.
Subjects and methods |
We studied 29409 patients who had both baseline preprocedure and peak postprocedure serum creatinine measured at the time of their percutaneous coronary intervention (PCI). Baseline demographics and creatinine profile before and after the procedure were compared between patients who received preprocedure statins and those who did not. CIN was defined as an increase in serum creatinine of ≤0.5 mg/dL.
Results |
Baseline serum creatinine was similar between the two groups. When compared with patients who did not receive preprocedure statins, patients on preprocedure statins had a lower incidence of CIN (4.37 vs 5.93, P <0.0001) and nephropathy requiring dialysis (0.32 vs 0.49, P = 0.03). After adjustments for comorbidities, preprocedure statin use was associated with a significant reduction in CIN (odds ration [OR] 0.87, 95% confidence interval [CI] 0.77–0.99, P = 0.03).
Conclusions |
Preprocedure statin use is associated with significant reduction in CIN after contemporary PCI. This reinforces the need to initiate statin therapy before percutaneous coronary interventions.
Le texte complet de cet article est disponible en PDF.Keywords : Kidney, Angioplasty, Contrast media, Lipids, Contrast nephropathy
Plan
Vol 118 - N° 8
P. 843-849 - août 2005 Retour au numéro
Article précédent
- Time tells the tale
- Jason E. Faris, Cynthia D. Brown
- Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer
- Steven B. Zeliadt, Ruth D. Etzioni, David F. Penson, Ian M. Thompson, Scott D. Ramsey
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?